Association between the administration of phenylbutazone prior to racing and musculoskeletal and fatal injuries in Thoroughbred racehorses in Argentina.
Abstract: To examine the association between prerace administration of phenylbutazone and the risk of musculoskeletal injury (MSI) and fatal injury in Thoroughbred racehorses that raced between 2006 and 2015 at 2 of the 4 official racetracks in Argentina. Methods: Data from racetrack databases and veterinary reports on 283,193 race starts. Methods: Data were collected relating to race performance and injury outcomes for starts at these tracks. The incidence of MSI and fatal injury was calculated for each year, stratified by the declared prerace administration of phenylbutazone. Univariable logistic regression, followed by multivariable logistic regression, was used to identify significant risk factors for both MSI and fatal injury. Results: Analyses identified associations between the declared prerace administration of phenylbutazone and the risk of MSI and fatal injury during racing. Horses with declared prerace phenylbutazone administration had greater odds of MSI (OR, 1.45 [95% CI, 1.03 to 2.04]) and fatal injury (OR, 1.59 [95% CI, 1.1 to 2.27]) than did horses racing without prerace phenylbutazone administration. These associations remained significant when other risk factors were accounted for in both multivariable models. Conclusions: Results suggested an association between the prerace administration of phenylbutazone and the risk of MSI and fatal injury in Thoroughbred racehorses during racing. Although these results did not imply a direct causal relationship between prerace phenylbutazone administration and injury, they may be considered in the development of more conservative medication policies to optimize racehorse welfare in North and Latin America.
Publication Date: 2020-08-29 PubMed ID: 32856998DOI: 10.2460/javma.257.6.642Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
- Journal Article
Summary
This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.
This research investigated the link between the use of phenylbutazone before a race and the risk of musculoskeletal and fatal injuries in Thoroughbred racehorses in Argentina. The study found that horses given phenylbutazone prior to racing had higher odds of both types of injuries, thus indicating a significant association and emphasising the need for more cautious medication policies to improve racehorse wellbeing.
Methods
- The study focused on Thoroughbred racehorses in 2 of the 4 official racetracks in Argentina, with races taking place between 2006 and 2015.
- Data on 283,193 race starts was gathered, with information relating to race performance and outcomes of injuries obtained from racetrack databases and veterinary reports.
- The researchers calculated the annual incidence of musculoskeletal injury (MSI) and fatal injury, differentiated by whether phenylbutazone was administered before the race.
- To identify significant risk factors for MSI and fatal injury, the team used univariable logistic regression. This was followed by multivariable logistic regression to control for the impact of other risk factors.
Results
- On analyzing the data, associations were found between the prerace administration of phenylbutazone and increased risk of both MSI and fatal injury while racing.
- Horses that received phenylbutazone before racing showed greater chances of sustaining an MSI (odds ratio or OR, 1.45; confidence interval or CI, 1.03 to 2.04]) and fatal injury (OR, 1.59; CI, 1.1 to 2.27) as compared to horses that were not medicated prior to the race.
- These associations held up when other risk factors were considered in the multivariable models.
Conclusions
- The results indicated a potential link between the administration of phenylbutazone before a race and the risk of MSI and fatal injury in Thoroughbred racehorses.
- Although these results do not necessarily mean that prerace administration of phenylbutazone directly causes injuries, they suggest its use as a significant risk factor.
- The findings of this study could support the development of conservative medication policies for racehorses in North and Latin America, aiming to enhance their welfare.
Cite This Article
APA
Zambruno T, Georgopoulos SP, Boden LA, Parkin TDH.
(2020).
Association between the administration of phenylbutazone prior to racing and musculoskeletal and fatal injuries in Thoroughbred racehorses in Argentina.
J Am Vet Med Assoc, 257(6), 642-647.
https://doi.org/10.2460/javma.257.6.642 Publication
Researcher Affiliations
MeSH Terms
- Animals
- Argentina / epidemiology
- Horses
- Incidence
- Logistic Models
- Phenylbutazone / adverse effects
- Retrospective Studies
- Risk Factors
Use Nutrition Calculator
Check if your horse's diet meets their nutrition requirements with our easy-to-use tool Check your horse's diet with our easy-to-use tool
Talk to a Nutritionist
Discuss your horse's feeding plan with our experts over a free phone consultation Discuss your horse's diet over a phone consultation
Submit Diet Evaluation
Get a customized feeding plan for your horse formulated by our equine nutritionists Get a custom feeding plan formulated by our nutritionists
